Answers are grounded in this paper and cite their sources.
Cancer remains a leading cause of morbidity and mortality worldwide, and the search for noninvasive markers for cancer screening and diagnosis, as well as for patient monitoring, is of utmost importance to better and earlier detect cancer. As the second most abundant cell type in the bloodstream, platelets interact bidirectionally with cancer cells, acquiring cancer-associated molecular alterations that modify their transcriptomic profile and give rise to so-called tumor-educated platelets (TEPs). As an easily accessible and abundant blood component, TEPs have emerged as a promising liquid biopsy source for cancer diagnostic biomarkers. This systematic review aimed to evaluate the clinical utility of the TEP transcriptome as a potential source of diagnostic biomarkers in solid and hematological neoplasias. It also identifies the major challenges and future perspectives for their clinical implementation. The review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO: CRD42024486960).
No takes yet. Share an insight, caveat, or question.
Jorge et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: